

ISAD-2025



6th Edition of Innovations and State of the Art in
ALZHEIMER'S & DEMENTIA
October 01-02, 2025 at Berlin, Germany



Email: dementiacongress@innovinc.org | Web: <https://alzheimers-dementia.org/>

Phone: +1-408-465-0048 | Whatsapp: +1-408-352-1010

6th Edition of Innovations and State of the Art in **ALZHEIMER'S & DEMENTIA** October 01 - 02, 2025 at Berlin, Germany

Scientific Program

Day -1 October 01, 2025

Meeting Hall-Conference 2

Registrations Open (08:00-08:45)

Welcome Ceremony (08:45-09:00)

Moderator:

Anne-Cathrine Vogt, *University of Bern, Switzerland*

Keynote Talks

Grzegorz Węgrzyn,
*University of Gdansk,
Poland*

09:00-09:30

Genistein (4',5,7-trihydroxyisoflavone) corrects behavior and improves biochemical parameters in animal models of Alzheimer's disease through autophagy stimulation

Xianlin Han,
*University of Texas Health
Science Center at San
Antonia, USA*

09:30-10:00

Alzheimer's disease is likely a lipid-disorder complication as revealed by functional lipidomics and animal models

**José Julio Rodríguez
Arellano,**
*IKERBASQUE, Basque
Foundation for Science,
Spain*

10:00-10:30

Neurogenesis And Plasticity Processes Are Similarly Affected And Damaged In Alzheimer's Disease

Group Photo & Refreshment Break (10:30-10:50)

Technical Session-I

Session Chairs:

Grzegorz Węgrzyn & José Julio Rodríguez Arellan

Amanda J. Myers,
*University of Miami Miller
School of Medicine, USA*

10:50-11:10

Changes in expression of *VGF*, *SPECC1L*, *HLA-DRA* and *RANBP3L* act with *APOE E4* to alter risk for late onset Alzheimer's disease

Earvin Liang,
*Alzheon Inc., Framingham,
MA, USA*

11:10-11:30

Phase 3 Results of Oral Valiltramiprosate in APOE4/4 Homozygotes with Early AD: Clinical and Volumetric Effects and their Correlations in the Prespecified MCI Subgroup

Garth D. Ehrlich,
*Drexel University College
of Medicine, USA*

11:30-11:50

The Alzheimer's Pathobiome Initiative: Using multiple global pan-domain and omic technologies to interrogate the link between infection and dementia

Matthew P. Janicki,
*University of Illinois
Chicago, USA*

11:50-12:10

Implications for the Down Syndrome Community of Availability of Anti-Amyloid Alzheimer's Drug Treatments

Marc Teichmann,
*Pitié-Salpêtrière University
Hospital, France*

12:10-12:30

Biological prognosis toolbox for Alzheimer's disease and other cognitive neurodegenerative diseases

Christiane Reitz,
*Columbia University,
USA*

12:30-12:50

Efficacy monitoring using amyloid and tau PET neuroimaging in Down syndrome populations

Johan Magnus Palmfeldt,
*Aarhus University,
Denmark*

12:50-13:10

Genetic covariance analysis of Alzheimer's disease and stroke implicates PHLPP1 as a shared locus in individuals of African ancestry

Lunch Break @ Restaurant 13:10-14:00

Tony Yuen,
*Icahn School of Medicine
at Mount Sinai, USA*

14:00-14:20

Blocking FSH action improves
memory in mouse models of
Alzheimer's disease

Gyungah R Jun,
*Boston University School
Of Medicine, USA*

14:20-14:40

Integrative Multi-Omics Analysis
of APOE Genotype-Dependent
Molecular Signatures in Alzheimer's
Disease

Irena K. Roterman,
*Jagiellonian University –
Medical College , Poland*

14:40-15:00

Three scenarios for amyloid
transformation

Charles R Joseph,
*Liberty University College of
Osteopathic Medicine, USA*

15:00-15:20

Cerebral Capillopathy Nexus of
Neurodegenerative disease

Varghese John,
*Mary S. Easton Center
for Alzheimer's Disease
Research and Care,
University of California Los
Angeles, USA*

15:20-15:40

Discovery of an ApoE4-Targeted
Small-Molecule SirT1 Enhancer as a
Candidate Drug for the Treatment of
Alzheimer's Disease

Irfan Chaudhuri,
Harvard University, USA

15:40-16:00

Heterogeneous treatment effects of
BCG vaccine on Alzheimer's disease
risk

Refreshment Break @ (16:00-16:10)

Technical Session-II

Session Chairs:

Garth D. Ehrlich & Matthew P. Janicki

Qifang Li,
Tongji university, China

16:10-16:30

One-week inpatient cognitive
behavioral therapy for insomnia: a
retrospective study

Keith N. Darrow,
*Worcester State University,
USA*

16:30-16:50

Hearing Loss & Tinnitus – Reducing the
Risk of Cognitive Decline

David Ndeti,
*University of Nairobi / Africa
Institute of Mental and Brain
Health, Kenya*

16:50-17:10

Advancing dementia screening, care,
and research in Kenya: challenges and
opportunities

Anne-Cathrine Vogt,
*University of Bern,
Switzerland*

17:10-17:30

Probing Monoclonal Antibody
Specificity for Designing Alzheimer's
Vaccines

M'hammed Aguenouz,
University of Messina, Italy

17:30-17:50

Blood neurofilament light chain and
phospho-Tau 181 in subjects with
mild cognitive impairment due to age-
related hearing loss

Day-1 Concludes

Day -2 October 02, 2025

Meeting Hall-Conference 2

Moderator:

Zahra Moussavi, *University of Manitoba & Riverview Health Center, Canada*

Keynote Talks

Michael G Agadjanyan,
*The Institute for Molecular
Medicine, USA*

08:30-09:00

Safety and immunogenicity of the MultiTEP platform-based A β vaccine, AV-1959R, for secondary preventive therapy of individuals with preclinical Alzheimer's

Mone Zaidi,
*The Icahn School of
Medicine at Mount Sinai,
USA*

09:00-09:30

Can we Treat Osteoporosis, Obesity and Neurodegeneration with a Single FSH-Blocking Drug?

Technical Session-III

Session Chairs:

Scott B. Selleck & Amanda J. Myers

Zahra Moussavi,
*University of Manitoba
AND Riverview Health
Center, Canada*

09:30-09:50

Short and Long-term Effects of Transcranial Alternating Electrical Stimulation Paired with Cognitive Exercises as a Treatment for Cognitive Impairment

**Anne Desprez &
Cartignies Cindy**,
*Centre Hospitalier de
Valenciennes, France*

09:50-10:10

Taking care of elderly patients with neurocognitive disorders in Valenciennes' Hospital Center

Refreshment Break (10:10-10:30)

**Ana Beatriz Quintes
Steiner**,
*Universidade Federal de
Sao Paulo (UNIFESP),
Brazil*

10:30-10:50

Older adults with dementia: knowledge and attitudes of physicians in health units

Brian Lithgow, <i>University of Manitoba, Canada</i>	10:50-11:10	The efficacy of Sham rTMS stimulation
Joon Pio Hong, <i>Asan Medical Center, University of Ulsan, South Korea</i>	11:10-11:30	A Proposed Role for Lymphatic Supermicrosurgery in the Management of Alzheimer's Disease: A Primer for Reconstructive Microsurgeons
Christine Gierke, <i>University of Chile, Chile</i>	11:30-11:50	Bridging the gender gap in mental health: Correlational insights and a sensitive proposal for addressing social isolation in Chilean older people
Gemma Casadesus, <i>University of Florida, USA</i>	11:50-12:10	Evaluation of Sepsis-induced mechanisms driving long-term CNS dysfunction and AD/DRD risk
Serdar Bozdog, <i>University of North Texas, USA</i>	12:10-12:30	Deep learning-based methods for the early prediction of Alzheimer's Disease
Christian L. Lauber, <i>Nationwide Children's Hospital, USA</i>	12:30-12:50	Non-inflammatory outcomes of P. gingivalis outer membrane vesicles exposure in the embryonic mouse brain
Lunch Break @ Restaurant 12:50-13:50		
Technical session- IV		
<u>Session Chairs:</u> Charles R Joseph & Michael G. Agadjanyan		
Jaana Ruotsalainen, <i>University of Jyväskylä, Finland</i>	13:50-14:10	The Speech Disappears, but the Music Remains

Vilmante Borutaite, <i>Lithuanian University of Health Sciences, Lithuania</i>	14:10-14:30	Extracellular Tau and S100A9 proteins induce phagoptosis of live neurons
Scott Selleck, <i>Pennsylvania State University, USA</i>	14:30-14:50	Heparan sulfate modified protein signaling and neurodegenerative disease
Earvin Liang, <i>Alzheon Inc., Framingham, MA, USA</i>	14:50-15:10	Valiltramiprosate Effects on Microstructural Integrity of Grey and White Matter in APOE4/4 Homozygotes with Early AD and their Correlations to Clinical Outcomes: MRI Mean Diffusivity Results from the 78-Week APOLLOE4 Phase 3 Trial
Aluru Parithathi, <i>Manipal School of Life Sciences, India</i>	15:10-15:30	Maternal and early life exposure induced AD- like pathophysiology
Refreshment Break @ (15:30-15:50)		
Zhihui Zhong, <i>West China Hospital, Sichuan University, China</i>	15:50-16:10	Semaglutide ameliorates Alzheimer's disease and restores oxytocin in APP/ PS1 mice and human brain organoid models
Judy Qiao, <i>Towncom International Group, USA</i>	16:10-16:30	Dihydromyricetin as a Dual-Target Neuroprotector: Clearing Tau and A β for Alzheimer's Disease Intervention
Victoria Mutiso, <i>Africa Institute of Mental and Brain Health, Kenya</i>	16:30-16:50	Genetic and biomarker research on dementia in rural Kenya: insights from the READD-ADSP project
Panel Discussions & End of the Day		
Closing Ceremony		

ISAD-2025



VIRTUAL SESSION

6th Edition of Innovations and State of the Art in
ALZHEIMER'S & DEMENTIA
October 01-02, 2025 at Berlin, Germany



Join Zoom Meeting

Meeting ID: 846 2476 9584

Pass code: 675077



Day -1 October 01, 2025

Virtual Presentations (Time Zone: CET)

Illana Gozes , <i>Tel Aviv University, Israel</i>	12:30-13:00	Keynote Talk: Sex-specific brain protection in the clinical scenario: the case of davuenticide
SERGEANT Nicolas , <i>University of Lille, France</i>	13:00-13:20	From Phenotype Drug Screening to Biological Target identification for Alzheimer's disease-modifying development
Erika Smeriglio , <i>University of Messina, Italy</i>	13:20-13:40	Negative Plasticity, Language Impairment and the Role of Artificial Intelligence in Alzheimer's Disease
Montse Romero-Mas , <i>University of Vic - Central University of Catalonia, Spain</i>	13:40-14:00	Enhancing the quality of life for family caregivers of people with Alzheimer's via virtual communities of practice
Matthew G Pontifex , <i>University of East Anglia, United Kingdom</i>	14:00-14:20	Uncovering the mechanistic basis of menopause mediated dementia vulnerability
Caroline Jose , <i>Vitalité Health Network, Canada</i>	14:20-14:40	Pre-existing cognitive disorders and Long COVID neurocognitive sequelae: Why Do We Know So Little?
Marie J. Hayes , <i>University of Maine, United States</i>	14:40-15:00	Sleep Movements and Respiratory Coupling as a Biobehavioral Metric for Early Alzheimer's Disease
Chitralli R. Mamlekar & Melissa A. Alunni , <i>Misericordia University, USA</i>	15:00-15:20	Successes and Challenges: Insights from the first six months of the CONNECT program
Raymond Scott Turner , <i>Georgetown University, USA</i>	15:20-15:40	Aging as a target for the prevention and treatment of Alzheimer's disease

Norman L. Cantor, <i>Rutgers University School of Law, USA</i>	15:40-16:00	Clinicians' Reluctance to Implement a Deeply Demented Patient's Advance Directive: A Broken Moral Compass
Suren A. Tatulian, <i>University of Central Florida, USA</i>	16:00-16:20	Amyloid β fragments that suppress oligomers but not fibrils are cytoprotective
Manju Sharma, <i>University of Georgia, USA</i>	16:20-16:40	Futuristic Alzheimer's therapy: acoustic-stimulated piezoelectric nanospheres for amyloid reduction
Alexander Shtilbans, <i>Weill Cornell Medicine, USA</i>	16:40-17:00	Combination therapy for neurodegenerative diseases
Arushi Kapoor, <i>University of Pennsylvania, USA</i>	17:00-17:20	Enhancing Alzheimer's Disease Care Across Veterans Affairs Clinics: A Multi-site Quality Improvement Initiative
Habbiburr Rehman, <i>Boston University, USA</i>	17:20-17:40	Association of Plasma Protein Risk Scores for Mild Cognitive Impairment and Alzheimer Disease in the Framingham Heart Study
Clifford R. Jack, <i>Mayo Clinic, USA</i>	17:40-18:00	Revised Criteria for Diagnosis and Staging of Alzheimer's Disease
William C. Wakefield, <i>Mayo Clinic, USA</i>	18:00-18:20	Variational autoencoder latent space as a robust and pragmatic clinical classification tool for neurodegenerative diseases
Bradley T. Christian, <i>University of Wisconsin- Madison, USA</i>	18:20-18:40	Efficacy monitoring using amyloid and tau PET neuroimaging in Down syndrome populations
Duygu Tosun, <i>University of California - San Francisco, USA</i>	18:40-19:00	Exploring the Relationship Between $A\beta$ and α -Synuclein Pathologies: Longitudinal CSF Analysis and Cognitive Decline in the ADNI

Ezra C. Holston,
*University of Nevada Reno,
USA*

19:00-19:20

An integrative review about electrophysiological biomarkers of cognitive impairment in Alzheimer's disease: A developing relationship

Dean Ornish,
*Preventive Medicine
Research Institute, USA*

19:20-19:40

Effects of intensive lifestyle changes on the progression of mild cognitive impairment or early dementia due to Alzheimer's disease: a randomized, controlled clinical trial

Ursula Sandau,
*Oregon Health & Science
University (OHSU), USA*

19:40-20:00

Cerebrospinal fluid miRNAs identify sex-dependent alterations in synaptic proteins in humans with Alzheimer's disease

Day-1 Concludes

Day -2 October 02, 2025

Virtual Presentations (Time Zone: CET)

Tai Kake, <i>The University of Auckland, New Zealand</i>	09:40-10:00	Cultural Adaptation of Cognitive Stimulation Therapy for Māori with Dementia (CST-Māori)
Jennifer Gamble, <i>Centenary Institute and University of Sydney, Australia</i>	10:00-10:20	The vasculature as a therapeutic target for Alzheimer's disease
Zachary Bailey, <i>Care Window, Australia</i>	10:20-10:40	CareWindow: Enhancing Communication for Seniors and Individuals with Disabilities
Qiqi Lyu, <i>Singapore General Hospital, Singapore</i>	10:40-11:00	Stem Cell-Derived Extracellular Vesicles: A Promising Strategy for Alzheimer's Disease Treatment
Yuan Cao, <i>Peking Union Medical College Hospital, China</i>	11:00-11:20	Structural Changes in Cerebral Microvasculature Induced by Ferroptosis Contribute to Blood-Brain Barrier Destruction in Alzheimer's Disease: An Autopsy Study
Antonio Carlo GALOFORO, <i>University of Pavia, Italy</i>	11:20-11:40	OXYGEN-OZONE THERAPY AND COGNITIVE FRAILTY: A NONPHARMACOLOGICAL APPROACH TO POTENTIALLY RESOLVE IMMUNE AND INFLAMMATORY DYSFUNCTIONS
Inga Stewart, <i>St Andrew's Healthcare, United Kingdom</i>	11:40-12:00	How do we co-produce care planning with people living with dementia?
Andrea Stoccoro, <i>University of Pisa, Italy</i>	12:00-12:20	From healthy aging to dementia: potential role of DNA methylation
Olga Asrun Stefansdottir, <i>University of Akureyri, Iceland</i>	12:20-12:40	Second Partnership and Dementia Care in a Blended Family: CaseStudy of a Wicked Problem
Paul Chazot & Yunxi Zhang, <i>Durham University, UK</i>	12:40-13:00	In vitro validation of RAR β -M, Elloraxine, for use in Alzheimers disease

Gessica Sala, <i>University of Milano-Bicocca, Monza, Italy</i>	13:00-13:20	Blood biomarkers for tracking the effects of multidomain interventions in preventing cognitive decline
Paul Chazot & Norah Alanazi, <i>Durham University, UK</i>	13:20-13:40	Concussion-Related Biomarkers in Retired Rugby Players and Implications for Alzheimer's Disease and ALS Risk: The UK Rugby Health Study
Michael D. Gallagher, <i>Whitehead Institute for Biomedical Research, USA</i>	13:40-14:00	High-throughput CRISPR screen of GWAS loci in microglia reveals novel risk genes and pathways for Alzheimer's and multiple sclerosis
Soodeh Moallemian, <i>Rutgers University–Newark, USA</i>	14:00-14:20	The Brain Tissue Properties Within the Cerebellum Play Role in Executive Functioning and Memory Performance in Healthy Older Adults
S. Ryan Greysen, <i>University of Pennsylvania School of Medicine, USA</i>	14:20-14:40	Gamification and Social Support to Increase Physical Activity among Older Adults at Risk for Alzheimer's Disease and Related Dementias
Monique T Mulder, <i>Erasmus University Medical Center, The Netherlands</i>	14:40-15:00	Supplementation of Seaweed Extracts to the Diet Reduces Symptoms of Alzheimer's Disease in the APPswePS1ΔE9 mouse model
Leslie M. Shaw, <i>University of Pennsylvania, USA</i>	15:00-15:30	Keynote Talk: Implementation of plasma p-tau217 in treatment trials: Feasibility and Scalability
Alison Buchholz, <i>The Johns Hopkins University School of Medicine, USA</i>	15:30-15:50	A randomized feasibility trial of the modified Atkins diet in older adults with mild cognitive impairment due to Alzheimer's disease
Juan Pablo De Rivero Vaccari, <i>University Miami Miller School of Medicine, USA</i>	15:50-16:10	Traumatic Brain Injury Worsens the Inflammatory Response in Mice With a Genetic Predisposition To Alzheimer's Disease: A Role for Inflammasome Signaling
Sarah E. Lutz, <i>University of Illinois at Chicago College of Medicine, USA</i>	16:10-16:30	Blood-brain barrier permeability contributes to cognitive impairment in the aftermath of SARS-CoV-2 infection: a role for cerebrovascular Wnt/beta-Catenin and Caveolin-1

Suvendra Bhattacharyya, <i>University of Nebraska Medical Center, USA</i>	16:30-16:50	miRNA Phase Separation in control of Alzheimer's Disease
Velasco-Rodríguez, <i>Luz del C, Universidad Veracruzana, Mexico</i>	16:50-17:10	Curcumin and omega-3 fatty acids: nutraceuticals against Alzheimer's disease
Ladan Ghazi Saidi, <i>University of Nebraska- Lincoln, USA</i>	17:10-17:30	New Language Learning as a Cognitive Intervention in Aging: Behavioral and Neuroimaging Evidence
Angela Van Sickle, <i>Texas Tech University Health Sciences Center, USA</i>	17:30-17:50	Compensate or rehabilitate? SLPs' current approach to dysphagia in dementia
Gregory J. Brewer, <i>University of California Irvine, USA</i>	17:50-18:10	How an energy-redox boost may rescue AD to restore autophagy and remove amyloid
Jinnie Jeon, <i>Adler University, Canada</i>	18:10-18:30	Enhancing cognitive functioning in dementia through at therapy: A randomized trial based on the Expressive therapies Continuum (ETC) framework
Meixiang Huang, <i>Johns Hopkins University, USA</i>	18:30-18:50	Inhibition of brain glutamate carboxypeptidase II (GCP II) to enhance cognitive function in HIV
Day-2 Concludes		

We wish to see you again at

7th Edition of Innovations and State of the Art in
ALZHEIMER'S & DEMENTIA
September 07-08, 2026 at Paris, France

Web: dementiacongress@innovinc.org | Email: <https://alzheimers-dementia.org/>

Phone: +1-408-465-0048 | Whatsapp: +1-408-352-1010



INNOVINC INTERNATIONAL

USA: 5201 Great America Pkwy #320, Santa Clara, CA 95054, United States
Ph: +1-408-465-0048

INDIA: F No 301, Balaji Nagar, Nizampet, Hyderabad, TS, 500072, India.
Ph: +918374242127